Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma

Documenti analoghi

• Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy
  di: Max Kraemer, et al.
  Pubblicazione: (2025)
• Gastric cancer immune microenvironment score predicts neoadjuvant chemotherapy efficacy and prognosis
  di: Shaoji Zhao, et al.
  Pubblicazione: (2024)
• Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer
  di: Osamu Maeda, et al.
  Pubblicazione: (2024)
• The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy
  di: Elizabeth L. Carpenter, et al.
  Pubblicazione: (2024)
• Barriers to resection following neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma: A national and local perspective
  di: Marc W. Fromer, et al.
  Pubblicazione: (2024)